$RFL Income Statement | Understand Stock

$RFL

$1.21 -$0.03 (2.42%) Close

$RFL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Loss

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Jul 31, 2025	FY2024 12 months to Jul 31, 2024	FY2023 12 months to Jul 31, 2023	FY2022 12 months to Jul 31, 2022	FY2021 12 months to Jul 31, 2021
REVENUE
Parking
Infusion Technology
Rental – Third Party
Rental – Related Party
Other – Related Party
Total revenue

COSTS AND EXPENSES
Selling, general and administrative
Cost of product revenue
Infusion Technology revenue
Product revenue
Total cost of product revenue
General and administrative
Research and development
In-process research and development expense
Depreciation and amortization
Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit
Impairment – Altira
Provision for losses on related party receivables
Loss on impairment of goodwill

Loss from operations
Interest expense, net
Interest income
Gain on sale of building
Impairment of investments - Other Pharmaceuticals
Loss on initial investment in Day Three upon acquisition
Day Three Labs Inc
RP Finance
Total loss on initial investment in Day Three upon acquisition

Numerator for loss per share from continuing operations
Realized gain on available-for-sale securities
Realized gain (loss) on investment in equity securities
Unrealized (loss) gain on investments - Hedge Funds
Unrealized gain on investment in equity securities
Cyclo Therapeutics Inc
Hedge Funds
Total unrealized gain on investment in equity securities

Realized loss on investment in equity securities
Realized gain on investment - Cyclo
Unrealized (loss) gain on investment - Cyclo
Unrealized (loss) gain on convertible notes receivable, due from Cyclo
Unrealized gain on investment - Hedge Funds
Recovery of receivables from Cornerstone
Interest expense
Other income
Other income, net
Loss before income taxes
Benefit from income taxes
Equity in loss of Day Three
Consolidated net loss from continuing operations
Loss from discontinued operations related to 520 Property
Gain on disposal of 520 Property
Income from discontinued operations
Consolidated net loss
Unrealized gain on available-for-sale securities
Foreign currency translation adjustment
Comprehensive loss
Comprehensive loss attributable to noncontrolling interests
Comprehensive loss attributable to noncontrolling interests
Comprehensive loss attributable to Rafael Holdings, Inc.
Basic and Diluted (in Dollars per share)
Basic and Diluted (in Shares)
Loss per share attributable to common stockholders
Continuing operations basic (in Dollars per share)
Discontinued operations basic (in Dollars per share)
Basic (in Dollars per share)
Diluted (in Dollars per share)
Weighted average number of shares used in calculation of loss per share
Basic (in Shares)
Diluted (in Shares)
Net loss attributable to noncontrolling interests
Unrealized loss on available-for-sale securities
Net loss attributable to Rafael Holdings, Inc.
OTHER COMPREHENSIVE LOSS
Consolidated Net Loss
Foreign Currency Translation Adjustment

Total Comprehensive Loss

Comments